Sifalimumab
Sifalimumab (MEDI-545) is an anti-IFNα monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. Sifalimumab can be used in systemic lupus erythematosus (SLE) research[1][2].
Product Specifications
CAS Number
1006877-41-3
Product Name Alternative
MEDI-545; MDX 1103
UNSPSC
12352203
Target
IFNAR
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/sifalimumab.html
Purity
99.46
Solubility
10 mM in DMSO
Smiles
[Sifalimumab]
Molecular Weight
(144.24 kDa)
References & Citations
[1]Merrill JT, et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis. 2011 Nov;70 (11) :1905-13.|[2]La Maestra S, et al. Brain microglia activation induced by intracranial administration of oligonucleotides and its pharmacological modulation. Drug Deliv Transl Res. 2018 Oct;8 (5) :1345-1354.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
ARP57446_P050-FITC 100 µL
Srgap1 Antibody - middle region : FITC (ARP57446_P050-FITC)
Sign In for Pricing
View Details 